pharma · Friedreich Ataxia · LRMR
Larimar Therapeutics
Larimar Therapeutics is a pharma organization headquartered in Bala Cynwyd, USA. It trades on NYSE under ticker LRMR. Primary therapeutic focus areas include Friedreich Ataxia. NovaPharmaNews links 3 clinical program(s),
Company details
- Status
- Public
- HQ
- Bala Cynwyd, USA
- Founded
- 2016
- Employees
- 82
- Programs
- 3
- Drugs
- 2
- Patents
- 5
Nomlabofusp, Placebo to Nomlabofusp
Phase 3 · small molecule · Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.
Nomlabofusp, Placebo to Nomlabofusp for Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85. is a Phase 3 program (small_molecule) at Larimar Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CLIN-1601-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Larimar Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.
- Status
- active
- Trials
- 1